U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-QSB

(Mark One)

|X| Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2000

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from __________ to ___________.

Commission file number 0-27282

ATLANTIC TECHNOLOGY VENTURES, INC.

(Exact name of small business issuer as specified in its charter)

Delaware	36-3898269
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

150 Broadway, Suite 1110, New York, New York 10038
(Address of principal executive offices)

(212) 267-2503
(Issuer's telephone number)

150 Broadway, Suite 1009, New York, New York 10038
(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No _____

Number of shares of common stock outstanding as of March 31, 2000: 5,302,378

Transitional Small Business Disclosure Format (check one): Yes ___ No X

INDEX

ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Balance Sheets

Assets		March 31, 2000	December 31, 1999
		(Unaudited)	
Current assets:			
Cash and cash equivalents	$	3,114,605	3,473,321
Accounts receivable		319,396	337,323
Prepaid expenses		37,599	17,414
Total current assets		3,471,600	3,828,058
Property and equipment, net		122,191	131,832
Investment in preferred stock		250,000	--
Other assets		2,901	--
Total assets	$	3,846,692	3,959,890
Liabilities and Stockholders' Equity			
Current liabilities - accounts payable and accrued expenses	$	495,944	542,759
Stockholders' equity:			
Preferred stock, $.001 par value. Authorized 10,000,000 shares; 1,375,000 shares designated as Series A convertible preferred stock		--	--
Series A convertible preferred stock, $.001 par value. Authorized 1,375,000 shares; 575,667 and 610,088 shares issued and outstanding at March 31, 2000 and December 31, 1999, respectively (liquidation preference aggregating $7,483,671 and $7,931,144 at March 31, 2000 and December 31, 1999, respectively)		576	610
Convertible preferred stock warrants, 117,195 issued and outstanding at March 31, 2000 and December 31, 1999		540,074	540,074
Common stock, $.001 par value. Authorized 50,000,000 shares; 5,106,405 and 4,815,990 shares issued and outstanding at March 31, 2000 and December 31, 1999, respectively		5,105	4,816
Common stock subscribed. 182 shares at March 31, 2000 and December 31, 1999		--	--
Additional paid-in capital		22,973,876	21,662,272
Deficit accumulated during development stage		(20,168,341)	(18,790,099)
		3,351,290	3,417,673
Less common stock subscriptions receivable		(218)	(218)
Less treasury stock, at cost		(324)	(324)
Total stockholders' equity		3,350,748	3,417,131
Total liabilities and stockholders' equity	$	3,846,692	3,959,890

See accompanying notes to consolidated financial statements.

ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Operations
(Unaudited)

		Three months ended March 31, 2000	Three months ended March 31, 1999	Cumulative period from July 13, 1993 (inception) to March 31, 2000
Revenues:				
Development revenue	$	912,481	--	1,994,991
License revenue		--	--	2,500,000
Grant revenue		13,009	--	190,010
Total revenues		925,490	--	4,685,001
Costs and expenses:				
Cost of development revenue		729,985	--	1,595,993
Research and development		109,439	560,339	8,484,004
General and administrative		1,504,498	370,850	15,172,926
License fees		--	--	173,500
Total operating expenses		2,343,922	931,189	25,426,423
Other (income) expense:				
Interest and other income		(40,190)	(64,221)	(1,198,656)
Interest expense		--	--	625,575
Total other (income) expense		(40,190)	(64,221)	(573,081)
Net loss	$	(1,378,242)	(866,968)	(20,168,341)
Imputed convertible preferred stock dividend		--	--	5,331,555
Preferred stock dividend issued in preferred shares		659,319	--	973,685
Net loss applicable to common shares	$	(2,037,561)	(866,968)	(26,473,581)
Net loss per common share - basic and diluted	$	(0.41)	(0.19)	
Shares used in calculation of net loss per common share - basic and diluted		4,968,921	4,573,009	

See accompanying notes to consolidated financial statements.

ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)

	Three months ended March 31, 2000	Three months ended March 31, 1999	Cumulative period from July 13, 1993 (inception) to March 31, 2000
Cash flows from operating activities:			
Net loss	$(1,378,242)	(866,968)	(20,168,341)
Adjustments to reconcile net loss to net cash used in operating activities:			
Expense relating to issuance of warrants	990,820	--	1,289,022
Expense relating to the issuance of options	--	--	81,952
Expense related to Channel merger	--	--	657,900
Compensation expense relating to stock options	--	--	208,782
Discount on notes payable - bridge financing	--	--	300,000
Depreciation	15,757	30,275	446,167
Loss on disposal of furniture and equipment	--	--	73,387
Changes in assets and liabilities:			
(Increase) decrease in accounts receivable	17,927	78,989	(319,396)
(Increase) decrease in prepaid expenses	(20,185)	10,237	(37,599)
Increase (decrease) in accrued expenses	(46,815)	(80,606)	495,944
Increase in accrued interest	--	--	172,305
Increase in other assets	(2,901)	--	(2,901)
Net cash used in operating activities	(423,639)	(828,073)	(16,802,778)
Cash flows from investing activities:			
Purchase of furniture and equipment	(6,116)	(4,696)	(647,846)
Increase in investment in preferred stock	(250,000)	--	(250,000)
Proceeds from sale of furniture and equipment	--	--	6,100
Net cash used in investing activities	(256,116)	(4,696)	(891,746)
Cash flows from financing activities:			
Proceeds from exercise of warrants	--	--	5,500
Proceeds from exercise of stock options	321,039	--	373,539
Proceeds from issuance of demand notes payable	--	--	2,395,000
Repayment of demand notes payable	--	--	(125,000)
Proceeds from the issuance of notes payable - bridge financing	--	--	1,200,000
Proceeds from issuance of warrants	--	--	300,000
Repayment of notes payable - bridge financing	--	--	(1,500,000)
Repurchase of common stock	--	--	(324)
Preferred stock dividend paid	--	--	(318)
Proceeds from the issuance of common stock	--	--	7,547,548
Proceeds from issuance of convertible preferred stock	--	--	10,613,184
Net cash provided by financing activities	321,039	--	20,809,129
Net increase (decrease) in cash and cash equivalents	(358,716)	(832,769)	3,114,605
Cash and cash equivalents at beginning of period	3,473,321	5,835,669	--
Cash and cash equivalents at end of period	$ 3,114,605	5,002,900	3,114,605
Supplemental disclosure of noncash financing activities:			
Issuance of common stock in exchange for common stock subscriptions	$ --	--	7,027
Conversion of demand notes payable and the related accrued interest to common stock	--	--	2,442,304
Cashless exercise of preferred warrants	--	--	30,069
Conversion of preferred to common stock	289	140	1,704
Preferred stock dividend issued in shares	659,324	--	973,690

See accompanying notes to consolidated financial statements.

ATLANTIC TECHNOLOGY VENTURES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
March 31, 2000 and 1999

(1) BASIS OF PRESENTATION

The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles for interim financial information. Accordingly, the statements do not include all information and footnotes required by Generally Accepted Accounting Principles for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the year ending December 31, 2000 or for any subsequent period. These financial statements should be read in conjunction with Atlantic Technology Ventures, Inc., and Subsidiaries' (the "Company") Annual Report on Form 10-KSB as of and for the year ended December 31, 1999.

(2) LIQUIDITY

The Company anticipates that their current resources, together with proceeds from an agreement between the Company and Bausch & Lomb Surgical will be sufficient to finance their currently anticipated needs for operating and capital expenditures for at least the next 12 months. In addition, the Company will attempt to generate additional capital through a combination of collaborative agreements, strategic alliances and equity and debt financing. However, the Company can give no assurance that they will be able to obtain additional capital through these sources or upon terms acceptable to them.

(3) COMPUTATION OF NET LOSS PER COMMON SHARE

Basic loss per common share is calculated by dividing net loss applicable to common shares by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is the same as basic net loss per common share, as common equivalent shares from stock options, stock warrants, stock subscriptions and convertible preferred stock would have an antidilutive effect because the Company incurred a net loss during each period presented.

(4) RECENTLY ISSUED ACCOUNTING STANDARDS

In December 1999, the staff of the Commission issued Staff Accounting Bulletin ("SAB") No. 101, Revenue Recognition in Financial Statements. SAB No. 101 summarizes certain of the staff's views in applying generally accepted accounting principles to revenue recognition in financial statements, including the recognition of non-refundable fees received upon entering into arrangements. SAB No. 101, as amended, must be adopted no later than the second quarter of fiscal years beginning after December 15, 1999 with an effective date of January 1, 2000 and the recognition of a cumulative effect adjustment calculated as of January 1, 2000. The Company is in the process of evaluating this SAB and the effect it will have on its consolidated financial statements and current revenue recognition policy.

(5) EMPLOYMENT AGREEMENTS

The Company entered into employment agreements with three executives during April, 2000. These agreements provide for the payment of sign on and year end bonuses in 2000 totaling $200,000 and annual base salaries aggregating $425,000. Each agreement has an initial term of three years and can be terminated by the Company, subject to certain provisions, with the payment of severance amounts that range from three to six months.

(6) PREFERRED STOCK DIVIDEND

On February 15, 2000, the Company's board of directors declared a payment-in-kind dividend of 0.065 of a share of series A convertible preferred stock per share of series A convertible preferred stock to the holders of shares of the series A convertible preferred stock as of the record date of February 2, 2000. The estimated fair value of this dividend of $659,319 was included in the Company's calculation of net loss per common share for the three months ended March 31, 2000.

(7) ISSUANCE OF STOCK WARRANTS

As more fully described in Note 8 to the Company's Annual Report on Form 10-KSB as of and for the year ended December 31, 1999, the Company entered into a Financial Advisory and Consulting Agreement with Joseph Stevens & Company, Inc. during January 2000 pursuant to which the Company issued three warrants to purchase an aggregate of 450,000 shares of its common stock to Joseph Stevens & Company, Inc. In accordance with EITF Issue No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services and other relative accounting literature, the Company is required to measure the expense associated with the warrants at each reporting date and recognize the appropriate portion of the expense at the end of each reporting period until the measurement date is reached (December 4, 2000 in this transaction). As a result, the Company recorded a general and administrative expense of $990,820 in the first quarter of 2000 based on the estimated value of the warrants as of March 31, 2000.

(8) INVESTMENT IN PREFERRED STOCK

The Company is a party to a letter of intent dated March 17, 2000, to acquire preferred stock representing a 35% ownership interest in a privately-held company that is currently developing next-generation high-speed fiber optic communications technologies. The purchase price for this ownership interest is $5 million in cash, 200,000 shares of the Company's common stock and a warrant to purchase 200,000 shares of the Company's common stock. The closing of this transaction, which is scheduled to occur in May 2000, is subject to the Company being satisfied with the results of its due diligence investigation, and is also subject to waiver by certain stockholders of the Company of their right to have their shares represent a fixed ownership interest, regardless of future issuances of capital stock.

Of the $5 million cash portion of the purchase price, the Company has paid $250,000 into escrow, to be released when the stockholder waivers referred to above are signed. An additional $750,000 is payable at closing, with the remainder payable in four quarterly installments of $1 million. If after closing the Company elects to not pay the balance of the cash purchase price, the Company's ownership interest in the investment would be reduced proportionately. The warrant would have a term of three years, and would be exercisable at $8.975 per share of common stock, but only if the market price of our common stock is $30 or more.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our results of operations and financial condition should be read in conjunction with our Annual Report on Form 10-KSB for the year ended December 31, 1999.

RESULTS OF OPERATIONS FOR THE QUARTER ENDED MARCH 31, 2000 AND 1999

In accordance with its license and development agreement, as amended, with us, Bausch & Lomb Surgical ("Bausch & Lomb") reimburses our subsidiary, Optex Ophthalmologics, Inc. ("Optex") for Optex' costs related to the development of the Catarex ((TM)) technology plus a profit component. In the first quarter of 2000, this agreement provided $912,481 of development revenue and the related cost of development revenue was $729,985. For the quarter ended March 31, 1999, no revenue or cost of development revenue was recognized as all reimbursements from Bausch & Lomb prior to the September 1999 amendment were accounted for as reductions of research and development expense and general and administrative expenses.

For the quarter ended March 31, 2000, research and development expense was $109,439 as compared to $560,339, net of Bausch & Lomb reimbursements of $508,867, in the first quarter of 1999, a decrease of 80%. The decrease is due to reduced expenditures on certain development projects.

For the quarter ended March 31, 2000, general and administrative expense was $1,504,498 as compared to $370,850, net of Bausch & Lomb reimbursements of $31,480 in the first quarter of 1999. The increase is largely due to the $990,820 of expense associated with warrants issued to Joseph Stevens & Company and an increase in fees for professional services of approximately $197,000. This increase is offset to a degree by reductions in marketing and payroll expenses.

For the first quarter of 2000, interest income was $40,190 compared to $64,221 in the first quarter of 1999, a decrease of 37%. The decrease is due to the decline in our cash reserves.

LIQUIDITY AND CAPITAL RESOURCES

From inception to March 31, 2000 we had incurred an accumulated deficit of $20,168,341 and expect to continue to incur additional losses through the year ending December 31, 2000 and the foreseeable future.

Our available working capital and capital requirements will depend upon numerous factors, including progress of our research and development programs; progress and cost of ongoing and planned preclinical and clinical testing; timing and cost of obtaining regulatory approvals; the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; competing technological and market developments; changes in our existing collaborative and licensing relationships; levels of resources that we devote to the development of manufacturing and commercializing capabilities; technological advances; status of competitors; our ability to establish collaborative arrangements with other organizations; our need to purchase additional capital equipment.

We anticipate that our current resources, together with proceeds from the Bausch & Lomb agreement, will be sufficient to finance our currently anticipated needs for operating and capital expenditures for at least the next twelve months. In addition, we will attempt to generate additional capital through a combination of collaborative agreements, strategic alliances and equity and debt financing. However, we can give no assurance that we will be able to obtain additional capital through these sources or upon terms acceptable to us.

At March 31, 2000, we had $3,114,605 in cash and cash equivalents and working capital of $2,975,656. We are also obligated, and contingently obligated, under consulting and lease agreements to pay certain amounts in the future.

We are party to a letter of intent dated March 17, 2000, to acquire preferred stock representing a 35% ownership interest in a privately-held company that is currently developing next-generation high-speed fiber optic communications technologies. The purchase price for our ownership interest is $5 million in cash, 200,000 shares of our common stock and a warrant to purchase 200,000 shares of our common stock. The closing of this transaction, which is scheduled to occur in May 2000, is subject to our being satisfied with the results of our due diligence investigation, and is also subject to waiver by certain stockholders of the company of their right to have their shares represent a fixed ownership interest, regardless of future issuances of capital stock.

Of the $5 million cash portion of the purchase price, we have paid $250,000 into escrow, to be released when the stockholder waivers referred to above are signed. An additional $750,000 is payable at closing, with the remainder payable in four quarterly installments of $1 million. If after closing we elect not to pay the balance of the cash purchase price, our ownership interest in the company would be reduced proportionately. The warrant would have a term of three years, and would be exercisable at $8.975 per share of common stock, but only if the market price of our common stock is $30 or more.

As to the contemplated minority acquisition in a fiber optics communications company, we do not currently have the full amount of the cash purchase price. If the market price of our common stock permits it, we intend to redeem our redeemable warrants, which would encourage the holders to exercise the warrants, thereby providing us with capital that we could apply towards the cash purchase price. Alternatively, we could raise the necessary amount through debt or equity financing, or a combination of both. It is, however, possible that we will not be able to raise the required amount.

RECENTLY ISSUED ACCOUNTING STANDARDS

In December 1999, the staff of the Commission issued Staff Accounting Bulletin or SAB No. 101, Revenue Recognition in Financial Statements. SAB No.101 summarizes certain of the staff's views in applying generally accepted accounting principles to revenue recognition in financial statements, including the recognition of non-refundable fees received upon entering into arrangements. This SAB, as amended, must be adopted no later than the second quarter of fiscal years beginning after December 15, 1999 with an effective date of January 1, 2000 and the recognition of a cumulative effect adjustment calculated as of January 1, 2000. We are in the process of evaluating this SAB and the effect it will have on our consolidated financial statements and current revenue recognition policy.

RESEARCH AND DEVELOPMENT ACTIVITIES

Preclinical and clinical studies with our primary technologies are proceeding according to plan.

Optex' development of the Catarex device is continuing in cooperation with Bausch & Lomb. Bausch & Lomb is preparing to file a 510(k) with the U.S. Food and Drug Administration, or the "FDA," for the Catarex device. In a 510(k) filing, a company requests that the FDA treat a given technology as substantially equivalent to an already approved technology, the aim being to greatly speed up the approval process. We anticipate that in the second quarter of 2000 Bausch & Lomb will meet with the FDA to discuss this filing.

Research by Gemini Technologies, Inc. ("Gemini") on the antisense enhancing technology is continuing. We are currently considering strategies to maximize the potential of the 2-5A Chimeric Antisense Technology. We have conducted research at our own laboratory facilities and have sponsored research at the National Institutes of Health (the "NIH") focusing on two main objectives: (1) to advance basic research with the 2-5A Chimeric Antisense Technology in order to improve the knowledge base of the technology, efficiency of synthesis and to potentially increase its broad-potential ("platform") clinical utility and (2) to develop a potential lead product candidate for the treatment of Respiratory Syncytial Virus ("RSV") infection. Research to date has been conducted primarily in in vitro systems and has included studies of infectious diseases (RSV), herpes, human immunodeficiency virus, certain cancers (chronic myelogenous leukemia, glioblastoma), conditions modulated by 5-alpha reductase and dihydrotestosterone receptors (acne and androgenic alopecia) and aspects of the interferon pathway that are mediated by PKR (a protein kinase enzyme).

In 1999, we completed a toxicology program required for entry into clinical trials. The results of the toxicity studies indicate that CT-3 poses a very low risk of unwanted effects in humans. We have begun the first clinical trial in Europe during April of 2000. We believe it is important that we conduct Phase I studies to determine CT-3's potential for detrimental central nervous system effects. The first trial will specifically address CT-3's potential to produce central nervous system effects resembling those of THC.

In addition to pursuing clinical trials in Europe, Atlantic filed an Investigational New Drug application, or "IND," with the FDA for CT-3 in April of 2000. The design of the complete clinical program will require additional toxicology testing and formulation development prior to beginning large-scale clinical trials.

PART II -- OTHER INFORMATION

Item 1. Legal Matters

Litigation Brought by Christopher R. Richied

On May 13, 1999, Christopher R. Richied filed suit against a group of defendants, including Atlantic, in the U.S. District Court for the Southern District of New York. This lawsuit is described in our Quarterly Reports on Form 10-QSB for the quarterly periods ended June 30, 1999 and September 30, 1999.

The parties are currently engaged in factual and expert-related discovery. Atlantic and all other defendants in this action are being jointly represented by the Wilmington, Delaware office of the law firm Skadden, Arps, Slate, Meagher & Flom LLP. We believe that the asserted claims are without merit and intend to defend vigorously the action instituted by the plaintiff. We further believe that the outcome of this suit will not be material to us.

Item 4. Submission of Matters to a Vote of Security Holders

On February 16, 2000, Atlantic filed with the Securities and Exchange Commission, and mailed to stockholders on or about the same date, a definitive proxy statement seeking stockholder proxies consenting to a proposal that Atlantic's certificate of incorporation be amended to change Atlantic's name from "Atlantic Pharmaceuticals, Inc." to "Atlantic Technology Ventures, Inc."

Approval of this proposal required the affirmative vote of a majority of the common stock and preferred stock, voting together as a class.

Atlantic's board of directors presented these proposals for stockholder consideration at a special meeting of stockholders held on March 17, 2000, for which there was a quorum. The proposal received the affirmative vote of more than a majority of those stockholders present in person or by proxy. The total number of shares of common stock voted was 2,928,972 out of the 4,832,501 shares entitled to vote. The total number of shares of preferred stock voted was 212,670 out of the 605,088 shares entitled to vote, with each share being entitled to 3.27 votes. Of the 3,624,406 votes cast, 3,601,198, or 99.4%, were in favor of the proposal, 22,027, or less than 1%, were against the proposal, with 1,001, or less than 1%, abstaining.

On March 21, 2000, Atlantic filed with the Secretary of State of Delaware a certificate of amendment of its certificate of incorporation effecting the name change authorized by the stockholders.

Item 5. Other Information

Appointment of New President and New Outside Director

On , May 3, 2000, Atlantic announced that it had appointed Frederic P. Zotos, Esq., as its new President, and that the Dr. A. Joseph Rudick, Atlantic's former President, had assumed the position of Chief Executive Officer; Nicholas J. Rossettos, CPA was appointed Chief Financial Officer. In addition, Atlantic announced that its board of directors had appointed Mr. Peter O. Kliem to fill a vacancy on the board of directors. Mr. Kliem serves an outside director, and has replaced Mr. Zotos on the board's compensation and audit committees.

Dividend Payments to Holders of Preferred Stock

Pursuant to Atlantic's Certificate of Designations, holders of shares of Series A preferred stock were entitled to receive, commencing February 7, 1999, dividends on each share of preferred stock, payable in kind, at the rate of 10% of the Dividend Base Amount of $13.00, payable semiannually in arrears. On February 15, 2000, Atlantic issued a payment-in-kind dividend of 0.065 of a share of preferred stock per share of preferred stock to holders of shares of preferred stock as of the record date of February 2, 2000, amounting to an aggregate of 35,448 shares. Atlantic recognized a dividend in the amount of $659,319 related to this issuance.

Relocation of Principal Office

Effective January 1, 2000, Atlantic relocated its principal office to a different floor of the same office building, and changed its telephone and facsimile numbers. The new office information is as follows:

Atlantic Technology Ventures, Inc.
150 Broadway Avenue, Suite 1009
New York, New York 10038
Telephone: (212) 267-2503
Facsimile: (212) 267-2159

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

None

(b) Form 8-K

Atlantic did not file any reports on Form 8-K in the quarter ending March 31, 2000.

SIGNATURES

In accordance with the requirements of the Exchange Act, Atlantic caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ATLANTIC TECHNOLOGY VENTURES, INC.

Date: May 11, 2000

/s/ A. Joseph Rudick, M.D.

A. Joseph Rudick, M.D.
Chief Executive Officer

Date: May 11, 2000

/s/ Nicholas J. Rossettos

Nicholas J. Rossettos
Chief Financial Officer
(Principal Accounting and Financial Officer)